D-0880-2017 Class II Terminated

Recalled by Forest Laboratories, LLC — Jersey City, NJ

FDA drug recall D-0880-2017 was initiated by Forest Laboratories, LLC on May 18, 2017 and is designated Class II. Reason for recall: Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets The recall status is terminated (terminated Nov 15, 2018). Affected quantity: 40,621 blister packs.

Recall details

Product Type
Drugs
Report Date
Jun 7, 2017
Initiation Date
May 18, 2017
Termination Date
Nov 15, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
40,621 blister packs

Product description

Saphris 10 mg (asenapine) sublingual tablets, 6x10 count blister packs, Rx only, Black Cherry Flavor, Manufactured by: Catalent UK Swindon, Zydis Ltd, Blagrove, Swindon, Wilshire SN5 BRU, UK Distributed by Forest Pharmaceuticals, Inc. subsidiary of Forest Laboratories, LLC, Cincinnati OH 45209 USA --- NDC 0456-2410-60; Shellpack containing 1 blister card --- NDC 0456-2410-06

Reason for recall

Labeling; Label Mixup; blister lidding foil and shell-pack labeled as 10 mg but package actually contains 5 mg tablets

Distribution pattern

Nationwide

Code information

Lots W00733 and W00946, exp Apr 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0880-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0880-2017. Report a data issue: hello@regdatalab.com.